Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
8
INBS Quote, Financials, Valuation and Earnings
Last price:
$1.33
Seasonality move
:
-22.56%
Day range:
$1.24 - $1.36
52-week range:
$1.00 - $11.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.62x
P/B ratio:
0.96x
Volume:
136.2K
Avg. volume:
150.6K
1-year change:
-69.21%
Market cap:
$5.8M
Revenue:
$3.1M
EPS (TTM):
-$35.48
Analysts' Opinion
-
Consensus RatingIntelligent Bio Solutions has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Intelligent Bio Solutions has an estimated upside of 802.26% from its current price of $1.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.33.
Fair Value
-
According to the consensus of 0 analysts, Intelligent Bio Solutions has 802.26% upside to fair value with a price target of -- per share.
INBS vs. S&P 500
-
Over the past 5 trading days, Intelligent Bio Solutions has underperformed the S&P 500 by -8.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Intelligent Bio Solutions does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Intelligent Bio Solutions has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Intelligent Bio Solutions reported revenues of $872.3K.
Earnings Growth
-
Intelligent Bio Solutions has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Intelligent Bio Solutions reported earnings per share of -$8.40.
Enterprise value:
2.2M
EV / Invested capital:
0.34x
Price / LTM sales:
0.62x
EV / EBIT:
--
EV / Revenue:
0.69x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.21x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.5M
Return On Assets:
-86.71%
Net Income Margin (TTM):
-326.77%
Return On Equity:
-176.44%
Return On Invested Capital:
-161.24%
Operating Margin:
-312.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $2.1M | $3.2M | $796.1K | $872.3K | |
| Gross Profit | -- | $559K | $1.5M | $232.3K | $346.8K | |
| Operating Income | -$8.1M | -$9.7M | -$10.5M | -$2.5M | -$2.7M | |
| EBITDA | -$8.1M | -$10.3M | -$9.1M | -$2.1M | -$2.4M | |
| Diluted EPS | -$130.20 | -$170.83 | -$35.48 | -$12.48 | -$8.40 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.9M | $15.9M | $8.2M | $2.7M | $6.5M | |
| Total Assets | $2.9M | $19.1M | $10.2M | $8.7M | $11.7M | |
| Current Liabilities | $5.9M | $2.8M | $2.4M | $6.8M | $5.7M | |
| Total Liabilities | $6M | $5.6M | $5M | $7.5M | $5.8M | |
| Total Equity | -$3M | $13.5M | $5.2M | $1.2M | $5.9M | |
| Total Debt | -- | -- | -- | $648.1K | $499.6K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$5.3M | -$6.8M | -$10.6M | -$1.3M | -$2.4M | |
| Cash From Investing | -$1.4M | -- | -- | -- | -- | |
| Cash From Financing | -- | $1.4M | $14.6M | -- | $42.5K | |
| Free Cash Flow | -$5.3M | -$6.8M | -$10.6M | -$1.3M | -$2.4M | |
INBS
Sector
Market Cap
$5.8M
$44.6M
Price % of 52-Week High
11.37%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-170.16%
-0.68%
1-Year Price Total Return
-69.21%
-29.09%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.42
200-day SMA
Sell
Level
$2.07
Bollinger Bands (100)
Sell
Level
1.25 - 1.79
Chaikin Money Flow
Sell
Level
-444.4M
20-day SMA
Sell
Level
$1.54
Relative Strength Index (RSI14)
Sell
Level
38.69
ADX Line
Buy
Level
7.14
Williams %R
Neutral
Level
-74.5098
50-day SMA
Sell
Level
$1.53
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
1.1B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.4746)
Sell
CA Score
(Annual)
Level (-4.0975)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.5288)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).
Stock Forecast FAQ
In the current month, INBS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The INBS average analyst price target in the past 3 months is --.
-
Where Will Intelligent Bio Solutions Stock Be In 1 Year?
According to analysts, the consensus estimate is that Intelligent Bio Solutions share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Intelligent Bio Solutions?
Analysts are divided on their view about Intelligent Bio Solutions share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Intelligent Bio Solutions is a Sell and believe this share price will drop from its current level to --.
-
What Is Intelligent Bio Solutions's Price Target?
The price target for Intelligent Bio Solutions over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is INBS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Intelligent Bio Solutions is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of INBS?
You can purchase shares of Intelligent Bio Solutions via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Intelligent Bio Solutions shares.
-
What Is The Intelligent Bio Solutions Share Price Today?
Intelligent Bio Solutions was last trading at $1.33 per share. This represents the most recent stock quote for Intelligent Bio Solutions. Yesterday, Intelligent Bio Solutions closed at $1.33 per share.
-
How To Buy Intelligent Bio Solutions Stock Online?
In order to purchase Intelligent Bio Solutions stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
